This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wakchoure, S. Articles by Selander, K. S. Search for Related Content PubMed PubMed Citation Articles by Wakchoure, S. Articles by Selander, K. S.

Bisphosphonates Inhibit the Growth of Mesothelioma Cells In vitro and In vivo

Authors' Affiliations: ¹ Department of Medicine, Division of Hematology-Oncology, University of Alabama at Birmingham and ² Birmingham Veteran's Administration Medical Center, Birmingham, Alabama

Requests for reprints: Katri Selander, Department of Medicine, Division of Hematology-Oncology, University of Alabama at Birmingham, WTI T558, 1824 6th Avenue South, Birmingham, AL 35294-3300. Phone: 205-975-5973; Fax: 205-975-5650; E-mail: Katri.Selander{at}ccc.uab.edu.

Purpose: Bisphosphonates (such as risedronate and zoledronate) are widely used inhibitors of bone resorption. Despite their in vitro antiproliferative effects in various cancer cells, bisphosphonates have not exhibited significant antitumor efficacy in animal models of visceral cancer, which may be due to their poor bioavailability. The diagnostic use of radioactive bisphosphonates has revealed the accumulation of bisphosphonates in mesothelioma, which prompted us to test the antitumor efficacy of bisphosphonates in this disease.

Experimental Design and Results: Treatment with either risedronate or zoledronate (2 x 10^–4 to 2 x 10^–6 mol/L) inhibited the growth of AB12 and AC29 mouse mesothelioma cells and induced the accumulation of unprenylated Rap1A in these cells. Both these in vitro effects were reversed by geranygeraniol, an end product of the mevalonate pathway that these bisphosphonates inhibit. Both bisphosphonates also induced the phosphorylation of the p38 mitogen-activated protein kinase in AB12 and AC29 cells. The inhibition of p38 augmented bisphosphonate-induced growth inhibition in these cells. Bisphosphonate-induced p38 phosphorylation was not reversible by geranylgeraniol. Risedronate (15 mg/kg) and zoledronate (0.5 mg/kg) inhibited the growth of s.c. tumors and increased the median survival of mice with i.p. mesothelioma tumors in vivo.

Discussion: In conclusion, risedronate and zoledronate inhibit the mevalonate pathway and induce p38 activation in mesothelioma cells in vitro. The effects on the mevalonate pathway dominate because the net result is growth inhibition. Both bisphosphonates also inhibit mesothelioma tumor growth in vivo and prolong the survival of mesothelioma-bearing mice. These results support further study of bisphosphonates in the management of mesothelioma.

This article has been cited by other articles:

				Y. C. G. Lee and S. Wilkosz Malignant Pleural Effusions: Fixing the Leaky Faucet Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 3 - 5. [Full Text] [PDF]

				A. J. Roelofs, K. Thompson, S. Gordon, and M. J. Rogers Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res., October 15, 2006; 12(20): 6222s - 6230s. [Abstract] [Full Text] [PDF]